Abstract 993
Background
Curative resection improves the outcome of the patients with local recurrence of rectal cancer (LRRC). On the other hand, the role of perioperative radiotherapy for LRRC still remains controversial.
Methods
To assess surgical treatment and perioperative radiotherapy for the patients with LRRC, 49 patients (male-female ratio, 29:20) who underwent the surgical treatment for LRRC in a single institution since 1990, were clinicopathologically analyzed.
Results
27 patients (55%) had radiotherapy (preoperative (pre): 15, postoperative (post): 12). The median dose of radiation was 60 Gy (28-72). Perioperative radiotherapy tended to be carried out for the patients with LRRC, which tumor location was close to pelvic wall. Total pelvic exenteration, abdominoperineal resection, tumor excisions, Hartmann’s operation, and low anterior resection were performed in 8, 21, 12, 6 and 2 patients, respectively. Out of 49 patients, 36 patients (73%) had curative resection (R0) and 13 patients (27%) had non-curative resection (R1, R2). R0 rate was higher in the patients without radiotherapy (86%) compared to the patients with radiotherapy (pre and post: 67% and 58%, respectively). Overall complications were observed in 39 patients (80%) after surgery for LRRC. The rate of intrapelvic abscess was doubled in the patients with preoperative radiotherapy compared to the patients without radiotherapy. The median operative time, blood loss, and hospital stay after surgery were 530 min, 1966 ml, and 40 days, respectively. The hospital stay after surgery was significantly longer in the patients with preoperative radiotherapy than the patients without radiotherapy (39 vs 66 days, p = 0.018). Three-years survival rate of all 49 patients and 36 patients with R0 resection were 56% and 64%, respectively. No three-years survivors were observed in the patients with noncurative resections (R2).
Conclusions
Curative resection improves the prognosis of the patients with LRRC. Preoperative radiotherapy may increase the complications, resulting in prolongation of patient’s hospital stay.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Hideaki Karasawa.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1310 - Upgrade of Low Grade Ductal Carcinoma in situ (DCIS): multimodality approach in a 10-year single institution study
Presenter: Ajung Chu
Session: Poster display - Cocktail
Resources:
Abstract
489 - Correlation between circulating tumor cells and the aromatase inhibitors therapy in postoperative patients with early breast cancer.
Presenter: Yumei Shi
Session: Poster display - Cocktail
Resources:
Abstract
838 - A Pilot Study of Single Pegfilgrastim Compared with Intermittent Every Other Days of 5 Shot-filgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) Chemotherapy (G-CSF 105 trial: NCT02685111)
Presenter: Jaeho Jeong
Session: Poster display - Cocktail
Resources:
Abstract
1337 - Painful scalp during chemotherapy induced hair loss is associated to permanent alopecia in breast cancer patients
Presenter: Nesrine Mejri
Session: Poster display - Cocktail
Resources:
Abstract
1445 - Breast cancer survival analysis in East Azerbaijan: five years cancer registry data in Iran
Presenter: Shima Pashaei
Session: Poster display - Cocktail
Resources:
Abstract
1457 - Is sarcopenia associated with increased toxicity of neoadjuvant/adjuvant chemotherapy for breast cancer?
Presenter: Ayako Ueno
Session: Poster display - Cocktail
Resources:
Abstract
759 - A Study on possibility of High Sensitivity C - reactive protein (hs-CRP) and Circulating Interluekin-6 (IL-6) as biomarker in Breast Cancer Patients
Presenter: Md Shah Jalalur Rahman Shahi
Session: Poster display - Cocktail
Resources:
Abstract
1447 - Correlation Between Expression of Topoisomerase II Alpha with Ki-67 and Tumor Size in Luminal B-Like Indonesian Breast Cancer Patients
Presenter: Helenia Putri
Session: Poster display - Cocktail
Resources:
Abstract
1175 - Association of Serum Vitamin D Level and Vitamin D Receptor Polymorphism (Apa 1) And Breast Cancer
Presenter: Suzy Gohar
Session: Poster display - Cocktail
Resources:
Abstract
911 - Prognostic Nomograms for Predicting Overall and Cancer-Specific Survival in Breast Cancer Patients Not Achieving Pathological Complete Response After Neoadjuvant Chemotherapy
Presenter: Jianguo Lai
Session: Poster display - Cocktail
Resources:
Abstract